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IgM, IgA, and IgG Rheumatoid Factors in Early Rheumatoid Arthritis 
Predictive of Radiological Progression?
M, A. van Leeuwen1, J. Westra1, P.LC.M< van Riel2, P.C. Limburg1, and M.H. van Rijswijk1
1Dept. Rheumatology, University Hospital Groningen, 2Dept. Rheumatology, University Hospital Nijmegen, The Netherlands
The significance of IgM, IgA and IgG rheumatoid factors (RF) for the prediction of radiological progression, and as process variables during 
follow-up, was evaluated in a three-year prospective study of 149 patients with early rheumatoid arthritis (symptoms < 1 year at study entry). 
The occurrence o f IgA-RF and IgG-RF at study entry without simultaneous occurrence of IgM-RF, and the seroconversion from RF-negative 
at entry to RF-positive during follow-up appeared to be unusual. A significant correlation was found between each of the RF-isotype levels at 
entry and radiological progression after three years. However, no significant prognostic value o f  IgA-RF and IgG-RF could be demonstrated if  
analysed in combination with IgM-RF, initial disease activity (as measured by C-reactive protein level), initial radiologic score, HLA-DR4 and 
HLA-DR2. Although IgM-RF levels generally reflected the course of disease activity and did so better than IgA-RF and IgG-RF levels, their 
clinical significance as process variables appeared to be limited compared to C-reactive protein.
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Rheumatoid arthritis (RA) is a heterogeneous disease 
with regard to disease expression and outcome. Several 
factors have been shown to be helpful in identifying in 
an early phase patients at risk for a poor prognosis (1). 
These prognostic factors include rheumatoid factor 
(RF), HLA-DR4 and HLA-DR2, sex, age and high 
initial disease activity, as assessed by number of active 
joints, erythrocyte sedimentation rate (ESR) or C-reac­
tive protein (CRP) levels (2 ,3 ). RF has long been used 
to distinguish ‘seropositive’ from ‘seronegative5 RA, 
the latter generally showing a milder course, The defi­
nition of seronegative RA is still a matter of debate 
(4—6), which may in part be related to selection of 
patients (i.e. exclusion of other forms of seronegative 
polyarthritides) and the sensitivity of the assays.
Since the development of enzyme-linked immuno 
assays (ELISA) for detection and quantitation of the 
different RF-isotypes, divergent conclusions on the 
prognostic significance of these RF-isotypes have been 
reported (7-9). Methodologic aspects of the assays, 
patient selection, and different analytical approaches 
may have contributed to these differences (10). In our 
prospective study of patients with early RA (11), we 
analysed the prognostic value of IgM-RF, IgA-RF and 
IgG-RF at entry, and their potential significance as 
process variables during follow-up. Special attention 
was given to the question of whether RF-isotype 
measurements yield information additive to other prog­
nostic factors or process variables. As technical aspects 
of the RF-isotype measurements may influence the
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conclusions, the assays were evaluated on the point o f  
pepsin digestion and IgM-RF interference.
Patients and methods
Consecutive patients with classical or definite RA ac­
cording to the 1958 ARA criteria, with joint symptoms 
for less than one year, who had not previously received 
second-line anti-rheumatic drugs (DMARDs), were in­
vited to participate in a prospective follow-up study. 
Data from 149 patients, with a follow-up of at least 3 
years, were analysed. All but 3 patients fulfilled also  
the 1987 ARA-criteria for Rheumatoid Arthritis (22). 
According to the protocol, at monthly visits, 52 peri­
pheral joints were examined for tenderness and soft 
tissue swelling, and blood samples were collected for  
laboratory measurements. Radiographs of hands and 
feet were obtained at study entry and after 3 years, and 
joint damage (erosions and joint space narrowing) was 
assessed according to Sharp with some modifications 
(12, 13). The maximum total score of this method is 
448. The progression of radiological damage was de­
termined as the difference between the total score at 
entry and after 3 years. Pelvic radiographs were made 
at entry and after 3 years to evaluate the occurrence o f  
sacroiliitis. ESR, CRP, and IgM-RF were measured in 
the monthly samples of all 149 patients. IgA-RF and 
IgG-RF were measured in samples of all patients at 
entry and every 6 months during follow-up. In addi­
tion, in the first 20 patients of the cohort measurements 
of IgA- and IgG~RF were performed monthly. For 
comparison between CRP, ESR, and IgM-RF with ra­
diological progression during the 3 years follow-up, 
time-integrated values of serial measurements of CRP, 
ESR, and IgM-RF were calculated (area under the 
curve). Patients were treated with non-steroidal anti­
inflammatory drugs and second-line antirheumatic
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drugs (DMARDs) as clinically indicated. Additional 
treatment with low-dose corticosteroids was allowed 
when necessary. Clinical remission was defined ac­
cording to the ARA criteria for remission (14).
Laboratory measurements
CRP was measured by ELISA (15), ESR according to 
Westergren.
HLA-DR typing was performed by the two colour 
fluorescence method (16).
IgM-RF, IgA-RF, and IgG-RF were measured by 
ELISA:
Antigens: Human IgG was isolated from a pool of 
normal sera by chromatography on DEAE-52 cellulose 
(Whatman). Rabbit IgG was purchased from Nordic 
(Tilburg, The Netherlands). Heat-aggregated human 
and rabbit IgG were prepared by heating 10 mg/ml IgG 
for 30 minutes at 63°C.
Antisera: For detection of IgM- and IgA-RF, per­
oxidase labelled F(ab')2 fragments of goat anti-human 
IgM (|i-chain specific) and anti-human IgA (a-chain 
specific) were used (Cappel, Organon Teknika, Turn- 
hout, Belgium). Mouse monoclonal antibodies against 
human IgG (IgG-Fd specific, clone HP6045) (17), ob­
tained from Calbiochem (San Diego, California USA), 
were used for detection of IgG-RF in combination with 
rabbit anti-mouse IgG conjugated to HRPO (Dako, 
Glostrup, Denmark).
RF standard preparations: the WHO International 
reference preparation for rheumatoid factor (WHO 
64/1), containing 500 IU/ml rheumatoid factor (18), 
and the Netherlands Reference Serum Preparation 
(NRSP) (19) were used in this study.
IgM-RF assay: Flat-bottomed 96-well microtitre 
plates (HyCult, Uden, The Netherlands) were coated 
by incubating each well with 40 ftg/ml heat-aggregated 
human IgG in 0.1 M carbonate, pH 9.6, at 37°C for one 
hour. The plates were washed with washing buffer 
(0.05 M tris-HCl, pH 8.0, 0.3 M NaCl, 0.05% Tween 
20). Of each serum sample four serial dilutions in 
washing buffer +2% BSA (starting at 1:100) were run 
in duplicate. In each assay a control serum was tested 
as well. After incubation for one hour at 37°C plus 
overnight at 4°C, the plates were washed and incubated 
for 30 minutes at 37°C with goat F(ab')2 anti-human 
IgM conjugate. The colour reaction was performed 
with an 0PD-H20 2 mixture. IgM-RF levels were ex­
pressed in international units (IU) by using the stan­
dard sample.
IgA-RF assay: according to the assay for IgM~RF, 
except for the use of the goat F(ab')i anti-human IgA 
conjugate.
IgG-RF assay: the method differed from the IgM-RF 
assay at the following points. Rabbit IgG was used as 
antigen. Prior to the assay, serum samples were diges­
ted with pepsin (Sigma) as described by Wernick (20).
Serial dilutions of treated serum samples were ana­
lysed starting at a dilution of 1:30. Bound IgG-RF was 
detected with mouse monoclonal anti-human IgG-Fd 
(HP6045), incubation for one hour at 37°C, followed 
by rabbit anti-mouse IgG-HRPO for 30 minutes at 
37°C.
Results o f IgA-RF and IgG-RF measurements were 
expressed in IU/ml assuming a concentration of 500 
IU/ml for all RF-isotypes in the WHO international 
reference preparation.
Cut-off points. Normal controls were recruited among 
apparently healthy members of the medical and nurs­
ing staff of the hospital (n = 50, 24 male, 26 female, 
age 22-61 yr, median 34.5 yr). Cut-off points were 
assessed requiring >97%  of the normal control sera 
having negative results. Consequently, values of IgM- 
RF a* 10 IU/ml, IgA-RF ;> 10 IU/ml, and IgG-RF s2 5  
IU/ml were considered positive. Intra- and inter-assay 
variations were <10% for all assays.
Data of control experiments on some technical aspects of 
the RF-assays
1. Comparison of aggregated human and rabbit IgG as 
antigen in the IgM-RF and IgA-RF assays: no sig­
nificant differences were found in absolute levels 
(r = 0.950, n =  113), nor in the discrimination between 
positive or negative results for either IgM~RF or 
IgA-RF (data not shown).
2. Influence of pepsin-digestion on IgG-antibody 
activity.
Anti-tetanus antibodies: post tetanus-revaccination 
sera (n = 32) were tested in an ELISA using tetanus 
toxoid (RIVM Bilthoven, Netherlands) coated plates 
(21). Anti-DNA antibodies were measured in SLE-sera 
(n = 25) by ELISA with calf thymus DNA (Sigma, St 
Louis, USA) as the antigen (21). IgG-RF was mea­
sured in sera from RA patients (n = 61). All sera were 
tested before and after pepsin-digestion (20) using the 
ITP6045 anti-IgG-Fd monoclonal antibody. In addition, 
anti-tetanus and anti-DNA antibodies were measured 
in untreated sera with goat anti-human IgG-Fc conju­
gate (Kallestadt, Austin, Texas USA).
Both untreated and peps in-digested sera o f RA pa­
tients were tested in the IgG-RF assay. No IgM-RF 
could be detected after pepsin treatment using the anti­
human ^t-chain conjugate as detecting antiserum, 
indicating that the Fc-parts of IgM-RF had been 
eliminated. In most samples lower IgG~RF levels were 
measured after pepsin pretreatment. The strongest re­
duction in concentration was seen in those samples 
containing a distinct amount o f IgM-RF (> 20 IU/ml), 
whereas only a slight or no reduction was found in 
samples with low (<20 IU/ml) IgM-RF levels. For 
comparison, the influence of pepsin digestion on other 
IgG-antibodies was assessed: both IgG anti-tetanus and
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F ig , / .  Results for IgG-RF, anti-tetanus (TET), and anti-DNA  
(DNA) antibodies before and after pepsin digestion: The antibody 
activity preserved after pepsin digestion is expressed as % o f  the 
antibody activity measured in untreated sera. A :  samples containing 
> 2 0  IU/ml IgM-RF; A :  samples containing < 2 0  IU/ml IgM-RF,
anti-DNA antibodies were evaluated* The results for 
IgG-RF, anti-tetanus, and anti-DNA are shown in 
figure 1. The antibody activity preserved after pepsin 
digestion is expressed as the percentage of antibody 
activity measured in untreated sera. Antibody levels 
measured with the anti-IgG-Fc conjugate and the anti- 
IgG-Fd mAb before pepsin treatment were comparable 
(data not shown). The results o f these control experi­
ments indicate that for IgG-RF measurement pretreat­
ment of sera with pepsin is necessary to eliminate the 
interference of IgM-RF, and that the pretreatment ac­
cording to Wernick did not significantly interfere with 
the IgG antibody activity.
3. Evaluation of mutual interference of RF-isotypes 
in the respective RF ELIS A ’s.
Because different RF-isotypes are often present in 
one serum sample, competition in binding to the solid
Table I. Influence of the addition of polyclonal or monoclonal IgM-RF on the 
results of the IgA-RF and IgG-RF ELISA (n=7)
Addition IgA-RF measured (IU/ml) IgG-RF measured (IU/ml)
1 2 3 4 5 6 7
<10 55 300 680 25 63 230
p-lgM-RF*) <10 53 275 800 29 58 240
m-lgM-RF*) <10 54 250 720 30 65 220
*) polyclonal (p) or monoclonal (m) IgM-RF added in a concentration of 
250 IU/ml
Table II. Patient characteristics at study entry (n = 149)
age (yrs)
- median (range) 53 16-77
sex f:m
- nr of patients (%) 94:55 63:37
initial CRP level (mg/l)
- median (range) 20 0.1-260
HLA-DR4
- nr of patients (%) 90 60
HLA-DR2
- nr of patients (%) 29 16
duration of complaints at study entry (wks)
- median (range) 26 6-52
phase antigen may occur, leading to ‘false’ low levels 
of the specific RF-isotype measured. Special attention 
was given to the interference of IgM-RF.
IgA- and IgG-RF concentrations were measured in 
RA-sera before and after the addition of an excess of 
IgM-RF to 7 different sera. For these experiments, RA 
sera (n = 7) were selected with low IgM-RF levels 
(< 20 IU/ml), but IgA- and IgG-RF concentrations in a 
wide range. For the addition of IgM-RF, both a serum 
with a high concentration of polyclonal IgM-RF (500 
IU/ml) but low IgA- and IgG-RF concentrations and a 
purified monoclonal IgM-RF preparation (500 IU/ml) 
were used. The monoclonal IgM-RF was isolated from 
plasma of a patient with IgM-cryoglobulinaemia. The 
results are shown in Table I and indicate that IgA and 
IgG-RF measurements were not significantly influen­
ced by the presence o f IgM-RF.
Statistics
Correlations were determined by Spearman’s rank cor­
relation. Multivariable regression analysis was per­
formed using radiological progression during 3 years 
as dependent variable and initial CRP level, initial 
radiological score (X-score), RF-isotypes, HLA-DR4 
and HLA-DR2, sex, and age as independent variables 
(2), Log-transformation o f radiological scores, RF con­
centrations, and CRP level was performed to correct 
for skewness. Chi-square test was used for comparison 
between groups.
Results
Characteristics o f  the patients at study entry are shown 
in Table II.
None of the patients developed clinical or radiologi­
cal signs of a seronegative spondylarthropathy or sa- 
croiliitis, nor any other identifiable rheumatic disorder 
other than RA during follow-up. In addition, no patient 
did show psoriatic skin- or nail lesions, chronic in­
flammatory bowel disease or uveitis, and none of the 
patients had a first degree family member with a sero­
negative spondylarthropathy. During follow-up, 133 
patients were treated with DMARDs, mainly hydroxy-
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Table ill. Profile of rheumatoid factor isotypes at study entry. Comparison between patients with and without radiological damage at entry, and between 
patients with and without radiological damage after 3 years
XD=0andX3=0 X0=0andX3>0 X0>0 Total
(n = 17) (n*48) (n = 84) (n = 149)
n % n % n % n %
IgM-RF positive 7 41.0 43 89.5 71 84.5 121 81.2
IgA-RF positive 4 23.5 43 89.5 72 85.7 119 79.8
IgG-RF positive 7 41.0 41 85.4 60 71.4 108 72.5
lgM+, lgA+, lgG-RF+ 2 11.7 39 81.2 58 69.0 99 66.4
lgM+, lgA-RF+ 2 11.7 3 6.2 12 14.2 17 11.4
lgM+, IgA-RF- 3 17.6 1 2.1 1 1.2 5 3.3
no isotype positive 6 35.3 3 6.2 10 11.9 19 12.8
X0 = radiologic score at entry; X3= radiologic score after 3 years; += positive
chloroquine, gold, and sulphasalazine, either as the 
single drug used during follow-up or in succession. Ten 
patients were treated with methotrexate or azathio- 
prine. Thirteen patients had additional low-dose corti­
costeroids at any time during follow-up.
Prognostic significance of RF-isotypes at entry for 
radiological progression
The percentages of patients with positive results for the 
respective RF-isotypes and for combinations of RF- 
isotypes at study entry are shown in Table III. The 
results are given for three subgroups of patients: 1. no 
radiological damage during the first 3 years, 2. without 
damage at entry, but with development of radiological 
damage during follow-up and 3. with radiological 
damage at entry. The percentages of patients with posi­
tive results for the different RF-isotypes were sig­
nificantly higher in group 2 and 3, compared to group 
1, whereas the differences between group 2 and 3 were 
not significant. The majority of patients had positive 
results for both IgM~RF and IgA-RF; only 5 patients 
were IgM-RF positive/IgA-RF negative and 3 patients 
were IgM-RF negative/IgA-RF positive (with IgA-RF 
levels of 10, 10, and 30 IU/ml) with 1 patient in group 
2 and 2 patients in group 3. IgG-RF was positive in 7 
IgM-RF negative patients (with IgG-RF levels of 2 5 -  
78 IU/ml), 3 patients in group 1, 2 in group 2 and 2 in 
group 3.
The concentrations of IgM-RF, IgA-RF and IgG-RF 
at entry were each significantly correlated (P< 0.001) 
to the radiological progression during the following 3 
years (figure 2) with a correlation coefficient of 0.483 
for IgM-RF, 0.453 for IgA-RF and 0.375 for IgG-RF.
To assess the prognostic significance of the RF- 
isotypes compared to other well known prognostic 
factors multiple regression analysis was performed 
with radiological progression during three years as 
dependent variable. The variability of the extent of 
radiological progression appeared to be explained for 
35% (R = 0.590) by the combination of initial CRP-
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level (as measure of initial disease activity), initial 
X-score, HLA-DR4, HLA-DR2, sex, and age, if ana­
lysed without RR If the initial IgM-RF level (as the 
only RF-isotype) was added to these independent vari­
ables in the analysis, the explained variance was 46% 
(R = 0.683) and the progression of radiological damage 
after three years appeared to be significantly related to 
the initial IgM-RF level, initial CRP level, initial X- 
score (all P < 0.001), absence o f  HLA-DR2 (P < 0.002), 
and younger age (P < 0 .05 ). N o significant contribution 
appeared to exist for HLA-DR.4 and sex. Finally, if the 
initial IgA-RF and IgG-RF levels were added to the 
independent variables, the explained variance of radio­
logical progression did not improve (47%, R = 0.687), 
with no significant contribution of IgG-RF and IgA-RF. 
If these analyses were performed with the initial RF- 
isotypes as 'positive’ or 'negative5 (instead of absolute 
concentrations), the combination of IgM-RF and IgA- 
RF performed slightly better than IgM-RF alone. The 
results of these multiple regression analyses show that 
the initial CRP level, initial X-score, absence of HLA- 
DR2, and initial IgM-RF level appear to be the major 
prognostic factors for the extent of radiological pro­
gression during the first 3 years, and that the initial 
IgA-RF and IgG-RF levels y ield  no additional informa­
tion to this prognosis.
For the subgroup of patients without erosions at 
entry (n = 65), the occurrence of IgM-RF appeared to 
discriminate patients who became erosive during the 
next three years from those who did not develop ero­
sions. However, no significant differences were found 
between the relative risks calculated with the results of 
IgM-RF alone, or with the results of both IgM-RF and 
IgA-RF, or with the results o f  all three RF-isotypes. To 
evaluate the contribution o f  the three RF-isotypes to 
the prediction of the extent o f  radiological progression 
in the subgroup of patients without erosions at entry, 
multiple regression analysis was performed with the
same independent variables. N o differences in the ex-
i
plained variance of the extent o f radiological progres­
sion were found if the analysis was performed with
M. A. van Leeuwen
1000 =
b
#
*•
• *
0
»a • *+ m * • * » #
»
* •  *
1
1
r I ir 11 ir
10
1— TTTTTTT
100
1000,
s
5
&
c
I
I
• t •
:
• ♦ • - • • • •*
• •
♦
« I III • éi# m  u r n # •  1
1
r " ' T  I r i I i n  I— I—I I r i I m—
10 100
X-progression
Fig. 2 . Relation between RF-isotype concentrations at entry and 
radiological progression during 3 years o f follow-up .a. IgM-RF; b. 
IgA-RF; c. IgG-RF; X-progr = radiological progression.
IgM-RF or IgA-RF as the only RF-isotype, both IgM- 
RF and IgA-RF, or all three RF-isotypes in combina­
tion with the other independent variables (HLA-DR4, 
HLA-DR2, initial CRP level, and age): the explained 
variance was about 45% for all these combinations. 
This means that also in the subgroup of patients with- 
out radiological damage at entry, IgA-RF and IgG-RF 
did not have additional prognostic significance with 
regard to radiological progression during the first 3 
years.
RF levels during three years follow-up
Seroconversion for IgM-RF (149 patients, monthly 
measurements):
28 patients (20%) were negative for IgM-RF at entry 
(Table III); 7 of these 28 patients were IgM-RF posi­
tive (> 10 IU/ml) at some time during follow-up (1-9  
monthly values per patient, in 4 patients in a continu­
ous period of at least 6 months). However, these IgM- 
RF concentrations were only slightly beyond the cut­
off level (mostly <15 IU/ml and occasionly between 
15 and 20 IU/ml). Twenty-one patients were thus per-' 
sistently IgM-RF negative (< 10 IU/ml). From the 121 
patients who were positive for IgM-RF at entry, 92 
patients were persistently positive during follow-up, 
and 29 patients were negative at some time, 22 of them 
for a period o f at least 6 months. This indicates that in 
most patients the changes are trend-like and not in­
cidental. The highest IgM-RF levels in these 29 pa­
tients were 11-800 IU/ml (median 50). The conversion 
from IgM-RF negative to positive never occurred 
within the first 6 months after presentation, whereas 
the conversion from positive to negative occurred 1-20 
months (median 12 months) after presentation. Thus, 
based on monthly measurements during the first 3 
years o f the disease and a cut-off level of 10 IU/ml, 
62% of the 149 patients were persistently IgM-RF 
positive, 14% persistently IgM-RF negative and 24% 
showed a seroconversion during follow-up (4% nega­
tive to “marginal” positive and 20% from positive to 
negative). If only the half-yearly results of IgM-RF 
were used, 66% of the 149 patients were classified as 
persistently IgM-RF positive, 16% persistently nega­
tive and 18% as patients with seroconversions (3% 
negative to positive and 15% positive to negative).
IgA-RF and IgG-RF: at entry 30 patients (20% of 
149) were IgA-RF negative and 41 patients (27%) 
IgG-RF negative (Table III). Using the 6-monthly re­
sults of the 149 patients, in 4 patients (2.5% of 149) a 
conversion from negative to positive was found for 
IgA-RF and in 5 patients (3%) for IgG-RF, whereas 
conversion from positive to negative was found in 14 
patients (9%) for IgA-RF and in 20 patients (13%) for 
IgG-RF. The patients showing conversions from IgA- 
RF or IgG-RF negative to positive were persistently 
IgM-RF positive with the exception o f one patient who
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Table IV. Intra-individual correlations between monthly IgM-RF, CRP, and nr 
of swollen joints over a period of 36 months for patients with IgM-RF levels 
a 10 lU/ml (n = 121), and the intra-individual correlations of monthly IgM-RF, 
IgA-RF, and IgG-RF levels with CRP and nr of swollen joints for a subgroup of 
20 patients
CRP nr of swollen joints
correlation coefficients correlation coefficients
mean 95% Cl mean 95% Cl
IgM-RF (n = 121) 0,453 0.429-0.477 0.340 0.312-0.367
IgM-RF (n = 20) 0.395 0.329-0.457 0.230 0.157—0.300
IgA-RF (n = 20) 0.197 0.124-0.269 0.318 0.248-0.385
IgG-RF (n = 20) 0.264 0.192-0.333 0.275 0.203-0,344
showed a conversion from negative to positive for 
IgM-RF as well. A conversion from IgA-RF or IgG-RF 
positive to negative was always accompanied by a 
significant decrease or seroconversion for IgM-RF. 
Like IgM-RF, conversions from IgA or IgG-RF nega­
tive to positive seems to be rather exceptional, while 
the opposite occurs more frequently.
Validation of the use of the results for 6 monthly 
measurements of IgA-RF and IgG-RF for the estima­
tion of seroconversions was performed by analysis of a 
subgroup of 20 patients with monthly measurements. 
In all patients showing a seroconversion from IgA-RF 
or IgG-RF positive to negative, the negative period 
lasted for at least 6 months. Conversion from IgA-RF 
negative to positive was not found in this subgroup, but 
conversion from IgG-RF negative to positive lasted 
also for at least 6 months in all cases. It may be 
concluded that changes in IgA~RF and IgG-RF have a 
trendlike pattern and are not incidental.
Relation between IgM-RF status and clinical remission
Thirty-five of the 149 patients had at least 1 period of 
clinical remission according to the ARA-criteria. Eight 
of these 35 patients were persistently IgM-RF negative. 
Of the 27 patients, who were IgM-RF-positive at entry, 
6 patients became negative during clinical remission, 
in 7 patients the IgM-RF concentration was significant­
ly decreased (>50%), and in 14 patients the IgM-RF 
concentrations remained in the same range during the 
periods of clinical remission.
RF-isotype concentrations in relation to clinical and 
laboratory parameters of disease activity
Intra-individual correlations between IgM-RF concen­
trations and both CRP levels and number of swollen 
joints were calculated (121 IgM-RF positive patients). 
The mean and 95% Cl (obtained after Z-transforma- 
tion) are shown in Table IV, indicating that in the 
majority of the patients IgM-RF levels fluctuate in 
concordance with disease activity as measured by CRP 
and swollen joints. In addition, the intra-individual
correlations between both IgA-RF and IgG-RF, and 
CRP and swollen joints were calculated for the 20 
patients with monthly results for the three RF-isotypes 
(Table IV). IgM-RF appears to perform better than 
IgA-RF and IgG-RF in their intra-individual relations 
with disease activity parameters.
Course of IgM-RF levels during follow-up in relation to 
radiological progression
To evaluate the global correlation between IgM-RF 
levels and radiological progression, time-integrated 
values o f serially measured IgM-RF levels were calcu­
lated for the 121 patients with positive results at entry. 
For comparison with other process variables, the cor­
relation between time-integrated values of CRP and 
time-integrated values of the number of swollen and 
pain ful joints with radiological progression were calcu­
lated as well. The results are shown in Table V. A l­
though a significant correlation between time-inte­
grated values of IgM-RF and radiological progression 
is found, the cumulative disease activity as assessed by 
CRP, ESR and swollen joints during follow-up is more 
predictive for the extent of radiological progression.
Discussion
The prognostic significance of RF-isotypes for radio­
logical progression in RA has been investigated in 
several studies (7 -9 , 23) with contradictory conclu­
sions about the significance of especially IgA-RF. We 
analysed the prognostic significance of RF-isotypes in 
a multiple regression analysis to assess their sig­
nificance in relation to other factors. In combination
with initial IgM-RF, HLA-DR4 and HLA-DR2, initial
CRP (as measure o f initial disease activity), and initial 
X-score, no contribution of IgA-RF or IgG-RF could 
be demonstrated to the prediction of the extent of 
radiological progression during the first 3 years of 
disease. This was found both for the whole patient 
group and for the subgroup of patients without radio­
logical damage at entry. The prognostic significance of 
IgA-RF has mainly been reported as the result of an 
analysis o f IgM-RF and IgA-RF separately and in dif­
ferent patient groups. A prognostic significance of IgA-
Table V. Correlations between time-integrated values of igM-RF, CRP, ESR, 
nr of swollen joints, nr offender joints, and radiological progression after 3 
years follow-up (n« 121)
X-progression
IgM-RF* 0,293$
CRP* 0.6081-
ESR* 0.4131
nr swollen joints* 0.5361*
nr tender joints* 0.105
* time-integrated values; t P <0.001; t P<0.01
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RF has been reported in patients with early synovitis 
(7) and in patients with slightly longer standing disease 
(9). Our study was performed in a well defined patient 
group with early definite or classical RA according to 
the 1958 ARA criteria, who had not previously re­
ceived DMARDs or corticosteroids. In addition no 
patient developed an arthropathy other than RA during 
a follow-up of at least three years. The stage of the 
disease seems to be of importance in the interpretation 
of the actual RF level and the classification as RF 
positive or negative, as seroconversion during the 
course of the disease is a well known phenomenon and 
may be related to changes in disease activity and/or 
DMARD treatment. Criteria for seronegative RA have 
been proposed to include a follow-up of at least 3 years 
(to exclude other forms of arthritis) and at least 3 
negative RF tests (4). This prospective follow-up study 
with monthly observations permitted detailed analysis 
of seroconversions for IgM-RF during the first years of 
the disease, with an initial measurement before drug 
treatment was instituted. Only a few patients converted 
from IgM-RF negative to positive, and their levels 
never exceeded borderline values. These borderline 
values should be interpreted in view of the fact that RF 
levels obtained with these sensitive quantitative assays 
are continuous variables and the cut-off level for the
by the finding that negative results for IgA-RF in IgM- 
RF positive patients did only occur in the lower range 
of IgM~RF values.
The association of HLA-DR4 with a more progres­
sive course of RA has been reported in several studies 
in hospital referred patients (3, 26). The relation be­
tween HLA-DR4 and RF-positivity in RA is less con­
clusive, which may in part be the result of poor defini­
tion of seronegative RA (4-6, 27, 28). In our study, no 
significant contribution of HLA-DR4 to the explained 
variance of radiological progression was found if ana­
lysed in combination with IgM-RF and the other prog­
nostic factors studied.
In contrast to HLA-DR4, HLA-DR2 appeared to 
contribute significantly to the explained variance of 
radiological progression, as a prognostic favourable 
factor. This is in agreement with earlier reports show­
ing a negative correlation between HLA-DR2 and the 
severity of erosions (29).
In the majority of our patients a significant intra­
individual correlation was found between IgM-RF 
levels and measures of disease activity (such as ESR, 
CRP, and swollen joints), and time-integrated IgM-RF 
values appeared to be related to radiological progres­
sion. Compared to the acute phase response and swol-
len joints however, IgM-RF seems to be a less suitable
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discrimination between positive/negative is defined process variable with regard to radiological progres- 
statistically using results in a normal population. The sion. 
low frequency of conversion from negative to (margi­
nal) positive is in agreement with the results of a 
community based follow-up study, showing that > 90% 
of patients with RF-positive recent-onset arthritis al­
ready had a positive RF-test in their pre-illness sera 
(24). Conversion from IgM-RF positive to negative 
was found more frequently. Similar results for sero- 
vonversions were found for IgG-RF and IgA-RF. Al­
though based on less frequent observations, this con­
clusion on seroconversions of IgA-RF and IgG-RF 
seems to be warranted in view of the comparison be­
tween monthly and 6-monthly IgM-RF measurements 
and the trendlike changes according to the monthly 
measurements of IgA-RF and IgG-RF in a subgroup of 
patients. Studies in patients with longer standing RA 
may thus have a greater risk to classify patients wrong­
ly as RF negative.
The occurrence of IgA-RF or IgG-RF at presentation 
without simultaneous occurrence of IgM-RF appeared 
to be exceptional (23, 25), Measurement of IgA and 
IgG-RF in addition to IgM-RF will thus hardly in­
crease the number o f RF-positive cases in early RA.
We found slight differences in the prognostic sig­
nificance of IgA-RF using the RF-isotype as absolute 
concentrations or as positive/negative in the multivari­
able regression analysis. This is not surprising, as only 
a few patients did have discrepant results in IgM-RF 
and IgA-RF positivity. For the absolute concentrations, 
the lack of contribution of IgA-RF may be explained
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